Ignite Creation Date:
2024-05-06 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02752035
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2016-04-22
Brief Title:
A Study of ASP2215 Gilteritinib by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
2215-CL-0201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Astellas Pharma Global Development Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None